Johnetta Blakely
Tennessee Oncology · 18 works · 440 citations · h-index 6
Top works
- Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer
- Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition
- Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
- A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer
- A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC)
- Phase II trial of pemetrexed (P) and gemcitabine (G) as first-line chemotherapy for elderly and/or poor performance status patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
- Retraction Note: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
- Second- and Third-line Treatment of Patients With Non–Small-Cell Lung Cancer With Erlotinib in the Community Setting: Retrospective Study of Patient Healthcare Utilization and Symptom Burden
- 211P Risk of recurrence (ROR) among patients (pts) with HR+/HER2− early breast cancer (EBC) involving 1-3 axillary lymph nodes (N1): A real-world evaluation
- Finding value in social media: A collaborative online communication platform linking providers to education and an online tumor board across a large community of oncology practices.
- Abstract P6-12-08: Phase II Multicenter Study of Docetaxel and Bevacizumab (Bev) +/− Trastuzumab as First-Line Treatment of Patients with Metastatic Breast Cancer (MBC)
- The effect of COVID-19 on revenue cycle staff.
- Patient-reported symptom complaints associated with 5FU + irinotecan (IRI) or oxaliplatin (OXALI) in colorectal cancer (CRC)
- Use of antiemetic prophylaxis and oral breakthrough medication for highly emetogenic chemotherapy (HEC) in a large community oncology network.
- Use of real-world data to understand barriers to interventional clinical trial enrollment in community oncology clinics (COC).
- Impact of embedded palliative care providers compared to externally available palliative care services on the number of patients receiving palliative care referrals in a large community oncology practice.
- P2-316: Phase II trial of pemetrexed and gemcitabine as first-line chemotherapy for elderly and/or poor performance status patients with stage iiib/iv non-small cell lung cancer (NSCLC)
- QIM19-138: Care Coordination Between Prescribers and the Specialty Pharmacy—Qualitative Insights Into Designing a Quality Improvement Program for Multisite Community Oncology Practices